Pyrazolopyrimidines And Related Analogs As Hsp90-inhibitors

Abstract

A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: wherein: R<SUP>1 </SUP>is halogen, -OR<SUP>1</SUP>, -SR<SUP>11 </SUP>or lower alkyl; R<SUP>2 </SUP>is -NHR<SUP>8</SUP>; R<SUP>3 </SUP>is selected from the group consisting of hydrogen, halogen, -SR<SUP>8</SUP>, -OR<SUP>8</SUP>, -CN, -C(O)R<SUP>9</SUP>, -CO<SUB>2</SUB>H, -NO2, -NR<SUP>8</SUP>R<SUP>10</SUP>, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R<SUP>4 </SUP>is -CHR<SUP>12</SUP>-, -C(O), -C(S), -S(O)-, or -SO<SUB>2</SUB>-; R<SUP>5 </SUP>is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents.


Claims
Download PDF
Document Preview
Document History
  • Publication: Dec 12, 2006
  • Application: Sep 20, 2004
    US US 94663704 A
  • Priority: Sep 20, 2004
    US US 94663704 A
  • Priority: Jul 26, 2004
    US US 59146704 P
  • Priority: Sep 18, 2003
    US US 50413503 P

Download Citation


Sign in to the Lens

Feedback